Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade
Open accessThe DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Abstract Purpose: Cancer immunotherapy is a potent treatment modality, but its clinical benefit depends on the tumor's immune profile. Here, we used mJX-594 (JX), a targeted and GM-CSF–armed oncolytic vaccinia virus, as a strategy to remodel the tumor microenvironment (TME) and subsequently increase sensitivity to αPD-1 and/or αCTLA-4 immunotherapy. Experimental Design: The remodeling of the TME was determined using histologic, flow-cytometric, and NanoString immune profiling analyses. JX was intratumorally injected into implanted Renca kidney tumors or MMTV-PyMT transgenic mouse breast cancers with or without αPD-1 and/or αCTLA-4. Various combination regimens were used to evaluate immunotherapeutic anticancer responses. Results: Intratumoral injection of JX remodeled the TME through dynamic changes in the immune system, as shown by increased tumor-infiltrating T cells and upregulation of immune-related gene signatures. This remodeling induced conversion of a noninflamed tumor into an inflamed tumor. JX virotherapy led to enhanced abscopal effects in distant tumors, with increased intratumoral infiltration of CD8+ T cells. A depletion study revealed that GM-CSF is an indispensable regulator of anticancer efficacy of JX. Dual-combination therapy with intratumoral JX and systemic αPD-1 or αCTLA-4 further enhanced the anticancer immune response, regardless of various treatment schedules. Of note, triple combination immunotherapy with JX, αPD-1, and αCTLA-4 elicited the most potent anticancer immunity and induced complete tumor regression and long-term overall survival. Conclusions: Our results show that intratumoral JX treatment induces dramatic remodeling of the TME and more potently suppresses cancer progression with immune-checkpoint blockades by overcoming resistance to immunotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Due to their immune stimulatory effects and their ability to change a noninflamed tumor to an inflamed microenvironment, strategies to combine oncolytic viruses with ICB have been considered for enhancing response to treatment”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Chon et al., 2019
Citations
Cites
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Although ICI monotherapy revolutionized the treatment landscape of cancer, its dramatic therapeutic response is confined to a subset of patients (1, 43).”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 1×
“Although ICI monotherapy revolutionized the treatment landscape of cancer, its dramatic therapeutic response is confined to a subset of patients (1, 43).”
BackgroundInnate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · cited 2×
“This outcome gave rise to the concept of immunologically "hot" or "cold" tumors: hot tumors respond well to ICIs because they are immunologically inflamed with TILs and show high expression of PD-L1, whereas cold tumors are refractory to ICIs because of the paucity of CD8þ TILs and immunosuppressive TME (9, 24).”
BackgroundMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 1×
“However, the clinical efficacy of ICIs is confined to tumors with a T cell–inflamed tumor microenvironment (TME) (7,8).”
BackgroundHegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000 · cited 2×
“Cancer immunotherapy with immune checkpoint inhibitors (ICIs) targeting PD-1 or CTLA-4 has demonstrated a potent and durable therapeutic efficacy and emerged as a new weapon in the war on cancer (1-6).”
BackgroundMethodPalucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820 · cited 1×
“Moreover, tumor vasculatures and stromal components may pose a barrier against intratumoral trafficking of T cells and their effector functions on tumor cells (11-13).”
BackgroundHeo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779 · cited 3×
“JX-594 is an oncolytic virus in the most advanced stage of clinical trials and acts through various mechanisms (27,32,33).”
BackgroundSelf-citationOncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 774 · cited 1×
“GM-CSF is the most commonly used therapeutic genetic payload of oncolytic viruses (18, 44, 45).”
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582 · cited 1×
“The triple combination therapy enhances anticancer immune responses in a spontaneous breast cancer model To validate the long-term immunotherapeutic efficacy of the triple combination therapy in immune-resistant tumors, we used the MMTV-PyMT transgenic mouse model, which is a spontaneous breast cancer model with intri…”
Method
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Turning Cold into Hot: Firing up the Tumor Microenvironment
Duan, Q., Zhang, H., Zheng, J., & Zhang, L. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.022 · Cited by 934
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Self-citationOptimizing oncolytic virotherapy in cancer treatment
Harrington, K., Freeman, D. J., Kelly, B., Harper, J., & Soria, J.-C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 513
Wu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 456
“Combination with oncolytic virus therapy Oncolytic virus therapy can increase the activities tumorspecific effector and memory T cells that attack tumor cells [226, 227].”
Background
Metadata
- Authors
- Chon, H. J., Lee, W. S., Yang, H., Kong, S. J., Lee, N. K., Moon, E. S., Choi, J., Han, E. C., Kim, J. H., Ahn, J. B., Kim, J. H., & Kim, C.
- Affiliations
- Yonsei University (KR)
- CHA University Bundang Medical Center (KR)
- 4SillaJen, Inc., Seoul, Republic of Korea.
- 2Laboratory of Translational Immuno-Oncology, Seongnam, Republic of Korea.
- Corresponding author
- Kim, Chan
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2019-03-01
- Volume
- 25
- Issue
- 5
- Pages
- 1612-1623
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2904883738
- Cited by
- 158
- References
- 52
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 28 · 2023: 18 · 2022: 23 · 2021: 36 · 2020: 28 · 2019: 7
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Funders
- National Research Foundation of Korea (NRF-2016R1C1B2014671)
- National Research Foundation (NRF-2016M3A9E8941664)
- MSIP MOHW (2015M3D6A1065644, HI15C3517)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- oncolytic vaccinia virus, tumor microenvironment remodeling, immune checkpoint blockade, anti-PD-1 therapy, CTLA-4 blockade, GM-CSF, intratumoral injection, abscopal effect, CD8+ T cells, tumor-infiltrating T cells, combination immunotherapy, immune-related gene signature
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Combined Modality Therapy, Disease Models, Animal, Genetic Vectors, Humans, Male, Mice, Transgenic, Models, Biological, Neoplasms, Biomarkers, Tumor, Vaccinia virus, Injections, Intralesional, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, CD8-Positive T-Lymphocytes, Xenograft Model Antitumor Assays, Cell Line, Tumor, Oncolytic Virotherapy, Oncolytic Viruses, Mice, Immunomodulation, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-1932
- The paper
- Chon, H. J., Lee, W. S., Yang, H., Kong, S. J., Lee, N. K., Moon, E. S., Choi, J., Han, E. C., Kim, J. H., Ahn, J. B., Kim, J. H., & Kim, C. (2019). Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-1932
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.